KIT exon 17 mutations are predictive of inferior outcome in pediatric acute myeloid leukemia with RUNX1::RUNX1T1

Abstract

AbstractBackgroundPediatric core binding factor acute myeloid leukemia (CBF‐AML), although considered a favorable risk subtype, exhibits variable outcomes primarily driven by additional genetic abnormalities, such as KIT mutations.ProcedureIn this study, we examined the prognostic impact of KIT mutations in 130 pediatric patients with CBF‐AML, treated uniformly at a single center over 4 years (2017–2021). KIT mutations were detected via next‐generation sequencing using a myeloid panel comprising 52 genes for most patients.ResultsOur findings revealed that KIT mutations were present in 31% of CBF‐AML cases. Exon 17 KIT mutation was most commonly (72%) seen with notable occurrences at the D816 and N822 residue in 48% and 39% of cases, respectively. The 3‐year cumulative incidence of relapse (CIR) and overall survival (OS) for patients with exon 17 KIT mutation were 36% and 40%, respectively, and was significantly worse in comparison to other site KIT mutations (3‐year CIR: 11%; OS: 64%) and without KIT mutation (3‐year CIR: 13%; OS:71%). Notably, the prognostic impact of KIT mutations was prominent in patients with RUNX1::RUNX1T1, but not in those with CBFB::MYH11 fusion. Additionally, a high KIT variant‐allele frequency (VAF) (>33%) predicted for a higher disease relapse; 3‐year CIR of 40% for VAF greater than 33% versus 7% for VAF less than 33%. When adjusted for site of KIT mutation and end‐of‐induction measurable residual disease, VAF greater than 33% correlated with poor OS (hazard ratio [HR]: 4.4 [95% CI: 1.2–17.2], p = .034).ConclusionExon 17 KIT mutations serve as an important predictor of relapse in RUNX1::RUNX1T1 pediatric AML. In addition, a high KIT VAF may predict poor outcomes in these patients. These results emphasize the need to incorporate KIT mutational analysis into risk stratification for pediatric CBF‐AML.